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Introduction: It has been suggested that reductions in chloroquine use may be followed by a resurgence of
chloroquine-susceptible falciparum malaria, and chloroquine might once again be an effective treatment
choice, which renews the importance of aspects related to its use and misuse. Therefore, we aimed to
estimate the prevalence of chloroquine-induced pruritus and to identify risk factors for its occurrence in
Mozambican University students.
Methods: A cross-sectional study was conducted at a private University in Maputo. Students were
approached in the classrooms to complete a self-administered questionnaire covering sociodemographic
characteristics, number of previous malaria episodes, utilization of antimalarial drugs, and life prevalence
of chloroquine induced pruritus.
Results: Among 795 respondents, 77.4% (601/777) reported at least one malaria episode and 73.2%
(542/740) had used chloroquine before. The life-prevalence of chloroquine-induced pruritus was 30.1%
(158/525). Pruritus tended to be more frequent when chloroquine was used for treatment compared with
prophylaxis only (31.2% vs. 10.3%, po0.05), and chloroquine use in the last malaria episode was less
frequent in participants recalling chloroquine-induced pruritus (52.3% vs. 65.1%, po0.05).
Conclusion: About one third of the black population using chloroquine experienced chloroquine-induced
pruritus at least once. This adverse reaction tended to be less frequent when lower doses of chloroquine
were used and to inﬂuence future anti-malarial therapeutic choices.
& 2008 SESPAS. Published by Elsevier Espan˜a, S.L. All rights reserved.Factores asociados a la aparicio´n de prurito por cloroquina durante el





Factores de riesgoR E S U M E N
Introduccio´n: Se ha sugerido que la reduccio´n en el uso de la cloroquina puede derivar en el resurgimiento
de la malaria falciparum sensible a la cloroquina, por lo que e´sta puede volver a ser un tratamiento efectivo
de eleccio´n, renovando la importancia de aspectos relacionados con su uso y su mal uso. Se pretende
estimar la prevalencia de prurito inducido por cloroquina e identiﬁcar los factores de riesgo asociados a su
ocurrencia en estudiantes universitarios de Mozambique.
Me´todos: Se realizo´ una encuesta transversal en una Universidad privada de Mozambique. Los estudiantes
fueron abordados en las aulas para completar un cuestionario autoadministrado, que contenı´a datos
sociodemogra´ﬁcos e informacio´n sobre el nu´mero de episodios previos de malaria, la utilizacio´n de
fa´rmacos antipalu´dicos y la prevalencia de prurito inducido por cloroquina.
Resultados: De los 795 que respondieron, el 77,4% (601/777) reporto´ al menos un episodio de malaria y el
73,2% (542/740) utilizo´ la cloroquina anteriormente. La prevalencia del prurito inducido por cloroquina
fue del 30,1% (158/525). El prurito tendio´ a ser ma´s frecuente cuando la cloroquina era utilizada
como tratamiento en comparacio´n con su uso proﬁla´ctico (31,2% vs. 10,3%, po0,05), y su empleo en el
u´ltimo episodio de malaria fue menos frecuente en los participantes que recordaban haber sufrido prurito
inducido por cloroquina (52,3% vs. 65,1%, po0,05).
Conclusio´n: Cerca de un tercio de la poblacio´n de raza negra que usa cloroquina tuvo al menos un episodio
de prurito inducido por este fa´rmaco. Esta reaccio´n adversa tendio´ a ser menos frecuente cuanto ma´s bajas
fueron las dosis de cloroquina utilizadas, e inﬂuenciaba las opciones futuras de fa´rmacos antipalu´dicos.
& 2008 SESPAS. Publicado por Elsevier Espan˜a, S.L. Todos los derechos reservados.Introduction
There are promising new insights on the development of novel
medicines for malaria therapeutics. Meanwhile, the choice
between available anti-malarial agents is being determined by
drug resistances, price, side effects, and adherence to treatment1,2.ado por Elsevier Espan˜a, S.L. TodoChloroquine treatment has remained the most common single
treatment for malaria chemo-suppression for many years.3
However, since the 1980s, parasite resistance to this drug has
emerged as a major challenge and chloroquine’s effectiveness was
lost in most parts of Africa.
Currently, the World Health Organization recommends arte-
misin-based combination treatments as ﬁrst-line therapy for
falciparum malaria in all endemic areas in Africa.3 However, it has
been suggested that reductions in chloroquine use may be
followed by a resurgence of chloroquine-susceptible falciparum
malaria throughout the African region,4,5 and chloroquine mights los derechos reservados.
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with other antimalarial drugs.5 Malawi was the ﬁrst country in
Sub-Saharan Africa to replace chloroquine as ﬁrst-line treatment
for malaria, and has recently experienced a resurgence of
chloroquine susceptible falciparum malaria, 12 years after its
withdrawal.5
Chloroquine is not associated with signiﬁcant serious adverse
events in antimalarial doses, but chloroquine-induced pruritus is
known to affect a large proportion of black patients, contributing
to poor compliance with anti-malarial treatment.6–8 The role of
the extensive use and misuse of antimalarial therapeutics for the
emergence of drug resistances is particularly evident, for which
the experience of adverse reactions could be a great contribu-
tor.1,2,9
In this study we estimated the prevalence of chloroquine-
induced pruritus and identiﬁed risk factors for this condition, in a
sample of Mozambican University students.Methods
We conducted a cross-sectional study of students enrolled at a
private University in Maputo, Mozambique, chosen in order to
comprise a large number of students and a relatively wide range
of degrees, encompassed in a single campus. The University had
nearly 1500 students.
Students were asked to read a declaration of consent, in which
the objectives of the study and the methods to be used for data
collection were described, in agreement with the Helsinki
Declaration. Only students who agreed to sign the informed
consent document were considered participants and asked to ﬁll
in the questionnaire. Students who agreed to participate were
asked to complete a self-administered questionnaire applied in
the classes, with the consent of the teachers.
In March 2004, 47 of the 55 classes in the institution were
systematically approached, comprising 829 students, distributed
among all diurnal classes and 21 of 26 nocturnal classes. In order
to shorten the period of data collection, a one week time frame
was set in order to synchronize the period that responses referred
to. During this time frame, absenteeism and schedule constraints
accounted for the impossibility to approach all classes and all
students in each class. Additionally, 32 students (3.9%) refused to
participate. The above-mentioned losses and refusals accounted
for the ﬁnal number of 795 participants that represented
approximately 50% of the total number of students in the
institution.
The questionnaire covered sociodemographic information,
number of previous malaria episodes, utilization of antimalarial
drugs (including speciﬁc questions for the use of chloroquine),
and life prevalence of chloroquine induced pruritus. The latter was
assessed through the close-ended question: )Have you ever had
intense pruritus, itching or scratching while using chloroquine?*
The use of antimalarial drugs in the last malaria episode was
assessed by a questionnaire where the malaria drugs were
presented as answering options in the following order: chloro-
quine, quinine, sulfadoxine-pyrimethamine, amodiaquine, halo-
fantrine, artemisinine/artesunate, meﬂoquine, lumefantrine+
artemether, tetracyclines/doxycycline, clindamycin, other.
Proportions were compared using the w2 test. The association
of sociodemographic factors and intended use of chloroquine
(prophylaxis, treatment, or both) with the occurrence of chloro-
quine induced pruritus, and the association between socio-
demographic factors and history of chloroquine induced pruritus
and the use of chloroquine in the last malaria episode, was
quantiﬁed through crude and age- and ethnicity-adjusted odds
ratios (OR) with 95% conﬁdence intervals (95%CI) computed byunconditional logistic regression. Data analysis was conducted
with Statas, version 9.2.Results
Among 795 respondents the median age was 23 years (range:
18 to 51 years), 58.7% were females, and 18.4% were attending a
health-related degree (pharmacy or dentistry).
70.7% (601/777) of the subjects had malaria at least once in
their lives, from which 92.0% (553/601) described the treatment
performed in the last episode. The most frequently used drugs
were chloroquine (59.9%), followed by sulfadoxine-pyrimetha-
mine (24.2%), quinine (17.9%), artemisinine/artesunate (4.5%),
tetracyclines/doxycycline (4.2%), halofantrine (4.0%), and meﬂo-
quine (0.9%).
73.2% (542/740) subjects reported to have used chloroquine
before, at least once, and the prevalence of chloroquine-induced
pruritus was 30.1% (158/525), more frequent in blacks (35.6% vs.
13.4%, OR ¼ 2.96, 95%CI: 1.65–5.28), and increased with age (from
22.0% in the age-group 18 to 25 years to 43.4% in those aged above
35 (OR ¼ 2.28, 95%CI: 1.38–3.78). The recall of pruritus associated
with the use of chloroquine increased with the number of malaria
episodes during life, from 13.8% in those with one episode to
44.4% in subjects with 5 or more episodes (OR ¼ 5.04, 95%CI:
2.49–10.20). Pruritus was more frequent when chloroquine was
used for treatment compared with prophylaxis only (31.2% vs.
10.3%, OR ¼ 2.74, 95% CI: 0.79–9.47) (Table 1).
In subjects having used chloroquine both for treatment and
prophylaxis, 13 (34.2%) reported pruritus only during treatment, 3
(7.9%) during treatment and prophylaxis, and none during
prophylaxis.
Among subjects reporting more than one malaria episode
during their lives, chloroquine use in the last episode was more
frequent in participants not recalling previous pruritus associated
with its use (65.1% vs. 52.3%, OR ¼ 1.57, 95%CI: 0.93–2.68), in
those having had malaria less often (65.0% vs. 53.0%, OR ¼ 1.65,
95%CI: 0.98–2.79), and in the younger subjects, compared with
those aged above 35 (61.4% vs. 47.8%, OR ¼ 1.97, 95%CI: 1.06–3.64)
(Table 2).Discussion
Thirty percent of adult students in this sample reported having
experienced pruritus while using chloroquine. Chloroquine-
induced pruritus was more frequent in blacks, and increased with
age with the number of previous malaria episodes and with
chloroquine dose. Subjects experiencing chloroquine-induced
pruritus were less keen to use chloroquine again than those not
recalling this adverse event.
Although we approached students in all diurnal and most
nocturnal classes and the proportion of refusals was low,
information was obtained from only half the institution students.
Females resulted overrepresented in our sample (58.7% vs. 50%
enrolled in the university). Although women are more likely to
use different types of medication,10,11 namely in this speciﬁc
population,12,13 it is not expected that this could also happen with
drugs used to treat acute life-threatening diseases such as malaria,
and therefore we do not expect that this aspect could have biased
our estimates. The population median age of 27 years in this
University, as collected from University statistics, was higher than
the observed in our sample. This could contribute to an under-
estimation of chloroquine induced pruritus prevalence, once we
found it increased with age.
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Table 1
Prevalence of chloroquine-induced pruritus in relation to age, ethnicity, number of malaria episodes, and intended use of chloroquine
na Prevalence of chloroquine-
induced pruritus, n (%)a
OR (95%CI)b OR (95%CI)c
Gender
Females 289 80 (27.7) 1 1
Males 232 77 (33.2) 1.22 (0.82–1.80) 1.00 (0.66–1.52)
Age (years)
18–25 259 57 (22.0) 1 1
26–35 121 40 (33.0) 1.76 (1.09–2.85) 1.54 (0.93–2.53)
36 and over 106 46 (43.4) 2.73 (1.68–4.44) 2.28 (1.38–3.78)
Ethnicity
Non-black 127 17 (13.4) 1 1
Black 390 139 (35.6) 3.46 (1.95–6.10) 2.96 (1.65–5.28)
Number of malaria episodes
0–1d 123 17 (13.8) 1 1
2–4 182 52 (28.6) 2.22 (1.20–4.11) 1.96 (1.04–3.68)
5 or more 81 36 (44.4) 5.12 (2.58–10.14) 5.04 (2.49–10.20)
Use of chloroquine
For treatment 480 149 (31.0) 1 1
Only for prophylaxis 29 3 (10.3) 2.31 (0.99–11.22) 2.74 (0.79–9.47)
OR (95%CI): Odds ratio (95% conﬁdence interval).
a The sum of subjects may vary due to missing data.
b Crude OR, computed for participants with information available for age and ethnicity.
c OR adjusted for age and ethnicity.
d Includes subjects using chloroquine for prophylaxis.
Table 2
Use of chloroquine in the last malaria episode according to sex, age, ethnicity, number of malaria episodes and previous occurrence of chloroquine-induced pruritus, in
subjects recalling two or more malaria episodes
n Use of chloroquine in the last
malaria episode, n (%)a
OR (95%CI)b OR (95%CI)c
Gender
Males 161 87 (54.0) 1 1
Females 127 80 (63.0) 1.35 (0.82–2.22) 1.42 (0.86–2.36)
Age (years)
18–25 145 89 (61.4) 1.93 (1.05–3.55) 1.97 (1.06–3.64)
26–35 61 35 (57.4) 1.46 (0.71–2.98) 1.33 (0.64–2.74)
36 and over 67 32 (47.8) 1 1
Ethnicity
Non-black 68 40 (58.8) 1.21 (0.66–2.21) 1.27 (0.69–2.34)
Black 215 125 (58.1) 1 1
Number of malaria episodes
2–4 186 121 (65.0) 1.65 (0.98–2.79) –
5 or more 83 44 (53.0) 1
Chloroquine-induced pruritus
Never 170 110 (64.7) 1.67 (0.99–2.82) 1.57 (0.93–2.68)
At least once 88 46 (52.3) 1 1
OR (95%Cl): Odds ratio (95% conﬁdence interval).
a The sum of subjects may vary due to missing data.
b Crude OR, computed for participants with information available for the number of malaria episodes.
c OR adjusted for the number of malaria episodes.
H. Gama et al. / Gac Sanit. 2009;23(4):306–310308In the present methodological approach data was collected at
the campus premises, leaving absent students unsampled. There-
fore a sort of )healthy worker effect* could account for a selection
bias as those less ﬁt are more prone for a higher consumption of
medicines and any type of adverse reaction to drugs, which would
then also contribute to an underestimation of the frequency of
chloroquine induced pruritus by our study, but it does not impair
comparisons with studies conducted under similar conditions.
The speciﬁc problem of recall bias or misclassiﬁcation of the
main variables for this investigation should not play an importantrole in this study, since malaria is a well-known disease, severe
enough to warrant the accurate recall of previous episodes,
chloroquine has been the drug more frequently used for its
treatment for a long time, and the chloroquine induced pruritus is
easily recognizable and recalled by patients. Itching lasts usually
for 1–3 days, and can persist for up to 7 days. It is mainly
generalized, but it can also affect only speciﬁc sites, like hands,
legs and feet, or perineum/genitaliae.14 The questionnaire was
structured to make clear that the information regarding pruritus
should refer only to )intense pruritus, itching or scratching while
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in this population yielded the unexpected result of an 18%
prevalence of self-reported allergy to chloroquine in black
subjects,15 which may reﬂect the highly frequent itching produced
by chloroquine in black patients and the recognition by the
patients of its association with the antimalarial treatment.
Regarding the accuracy of previous diagnoses of malaria, blood
test for Plasmodium were performed in 94% of the most recent
malaria episodes, and nearly half of the students had the last
malaria episode diagnosed by a private doctor/clinic, as shown in
a subsequent study conducted in the same population.13
University students do not seem to represent general Mozam-
bican population namely due to education level attained, and
social and cultural backgrounds. Moreover, the fact that our
sample was drawn from a private University further limits
representativeness regarding the country’s university population.
A previous study in this Mozambican population16 suggests that
these students have a pattern of utilization of medicines similar to
the observed in university students from developed countries.
Such an easy access could only account for preference for newer
antimalarial drugs other than chloroquine and therefore, for a
lower prevalence of chloroquine induced pruritus, compared with
the general population. In an investigation conducted in the same
setting13 informationwas also obtained regarding the antimalarial
treatment in the last episode, when applicable, as well as the date
of the last episode. The proportion of subjects using chloroquine
in the treatment of malaria was 57% when the last episode took
place before 2004, and 42%, 18% and 12% in the episodes occurring
respectively in 2004, 2005 and 2006. However, only one quarter of
the treatments with chloroquine were done in association with
other antimalarial drugs, and this proportion remained un-
changed in the last years, showing that the inadequate use of
chloroquine is still present in this highly educated population.
Chloroquine induced pruritus was shown to be frequent in
African subjects under chloroquine treatment, with prevalence
ranging from 16% to 64%.5,8,17,18 The previous studies differ
considerably in the characteristics of the populations and in the
methods used, which makes a direct comparison difﬁcult. In the
present study a high prevalence of chloroquine-induced pruritus
among black subjects was also noticed. A 1.9% prevalence has
been observed in Plasmodium vivax malaria patients treated with
chloroquine in Thailand,19 which is in accordance with the lower
prevalence observed in the non-black subjects in our study.
The etiology of chloroquine-induced pruritus appears to be
multifactorial. Direct release of histamine does not appear to be
its cause, nor other allergic mechanisms9,20,21 but rather an
interaction between the drug itself and the disease or the parasite,
leading to development of pruritus.9,20,21 Moreover, differences in
hepatic metabolism of chloroquine caused by genetic polymorph-
isms may also explain different patterns of chloroquine-induced
pruritus.17,22 Finally, an involvement of endogenous opioid
peptides in chloroquine induced itching modulation is possible.23
In our study life prevalence of chloroquine-induced pruritus
increased with age and doses of chloroquine (assuming the
intended use of chloroquine as a surrogate for dosage), which
could be related with pharmacokinetic aspects. There is evidence
suggesting an association between higher chloroquine levels and
decreased metabolism in pruritus susceptible subjects. This could
be affected either by age or by chloroquine dosage.20,22
In African countries where chloroquine has become ineffective
against Plasmodium falciparum, artemisin-based combination
treatments are now considered the best therapy for falciparum
malaria.24 Some authors suggest that reducing the use of
chloroquine in a region could result in a reemergence of
chloroquine sensitive Plasmodium falciparum, thus permitting
reintroduction of this affordable drug in combination with otherdrugs, to prevent the reemergence of resistance,5 while others
think it is still too early to lay chloroquine to rest.4
Chloroquine-induced pruritus compromises compliance with
treatment regimens and possible contributes to the emergence of
chloroquine resistant strains of Plasmodium falciparum.6–8 Retur-
ning or not to its primary place in antimalarial treatment,
compliance will still be an important challenge in anti-infective
therapy, in order to prevent the emergence of resistances.
In this study, a large proportion of responders recalled that this
adverse event inﬂuenced future anti-malarial therapeutic choices.
This observation may not apply to less educated subjects, with a
more difﬁcult access to less affordable drugs, but is similar in its
nature to the generalized problem of non-adherence to therapy,
one of the possible causes of growing parasite resistance in Africa.
About one third of the black population using chloroquine
experienced chloroquine induced pruritus at least once. This
adverse reaction tended to be less frequent when lower doses of
chloroquine were used and to inﬂuence future anti-malarial
therapeutic choices. Prevention of this effect could be achieved by
identifying therapeutically effective drug levels that are not high
enough to induce the reaction, or by restricting its use to less
susceptible groups.Competing interests
The authors declare no competing interests.
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